This article is more than 5 years old. Information may no longer be current.

FDA accepts new drug application for AC-170 from Nicox

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The FDA has accepted the new drug application for AC-170 to treat ocular itching associated with allergic conjunctivitis, according to a press release from Nicox.

The FDA granted priority review and assigned a Prescription Drug User Fee Act goal date of Oct. 18, which is indicative and contingent on information to be provided by Nicox during the review period.

Nicox is also expecting an FDA decision on latanoprostene bunod by the end of the year.